Hub : Traits :

Medication: Levothyroxine sodium

386 significantly associated models · 95 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	752566	1941929	1	1	2.3e-08	1.0e-07	1.4e-01	92	PUSL1
2	1	2288852	2761863	1	1	2.2e-08	4.4e-07	1.1e-01	90	MMEL1
3	1	18972776	20503710	1	1	1.3e-08	7.7e-08	4.0e-05	42	CAPZB
4	1	107418424	109188382	1	2	2.9e-29	2.1e-29	1.0e+00	100	VAV3
5	1	113236087	115222434	10	8	9.3e-37	9.0e-84	NaN	NaN	BCL2L15 DCLRE1B HIPK1 OLFML3 PHTF1 PTPN22
6	2	190818878	192254289	1	1	7.4e-08	8.4e-19	3.7e-15	21	NAB1
7	3	11350553	12928762	2	1	1.6e-08	1.0e-07	1.0e+00	100	TIMP4
8	4	148303195	150060844	1	1	1.7e-15	1.6e-16	1.0e+00	100	NR3C2
9	5	101392473	103061825	1	1	6.0e-09	4.2e-09	1.1e-01	93	PAM
10	6	25296606	26689223	1	1	1.3e-08	6.0e-14	1.4e-08	43	U91328.19
11	6	34026489	35542476	2	1	3.9e-08	1.5e-08	1.2e-01	92	UHRF1BP1
12	6	89941356	91704536	1	1	6.2e-25	4.0e-25	1.0e+00	100	BACH2
13	6	166651581	167841508	5	8	3.4e-20	3.6e-20	1.0e+00	100	AL133458.1 GPR31 RNASET2
14	7	99591418	100979310	1	1	2.2e-07	2.9e-07	1.0e+00	100	GIGYF1
15	8	8092025	8939373	4	1	2.9e-10	7.2e-12	1.0e+00	100	SGK223
16	8	60736025	62220903	1	1	8.8e-08	9.3e-08	1.0e+00	100	RAB2A
17	8	133633829	134394277	1	1	2.8e-07	2.0e-09	2.2e-04	62	TG
18	9	99581811	102081250	8	12	1.4e-38	2.8e-51	NaN	NaN	ANP32B C9orf156 COL15A1 FOXE1 NCBP1 TMOD1 TSTD2
19	10	5027660	6504126	2	2	5.5e-13	8.8e-14	1.1e-02	88	FAM208B IL15RA
20	11	35028935	35689490	1	1	1.1e-13	2.0e-15	2.7e-04	79	SLC1A2
21	11	60549966	62346131	7	1	4.7e-09	1.7e-08	7.2e-01	100	FADS2
22	12	55677395	57125879	5	1	2.6e-10	3.5e-10	1.0e+00	100	RAB5B
23	12	110233500	113517494	20	8	3.3e-38	1.7e-63	NaN	NaN	ADAM1A ALDH2 HECTD4 RP3-462E2.3 VPS29
24	15	38088200	39556796	1	1	4.7e-12	1.7e-13	1.0e+00	100	RASGRP1
25	17	39589083	41265776	3	1	1.6e-11	1.4e-11	1.0e+00	100	HSPB9
26	17	44788310	46474610	4	2	5.0e-10	2.4e-10	4.6e-04	69	EFCAB13 NPEPPS
27	19	4118871	5529588	2	2	7.2e-10	3.2e-16	2.2e-06	66	FEM1A TICAM1
28	19	49279612	50652095	1	1	3.1e-07	5.6e-07	1.3e-02	76	ALDH16A1
29	22	30233446	30820707	1	1	3.9e-08	4.3e-10	1.6e-03	74	HORMAD2
30	22	36867133	38292974	2	1	4.9e-15	1.9e-15	4.5e-05	74	C1QTNF6

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hypothyroidism (self reported)	40.36	48	44	97.8	0.99	2.5e-57	ADAM1A AL133458.1 ALDH16A1 ALDH2 ANP32B BACH2 BCL2L15 C1QTNF6 C9orf156 CAPZB DCLRE1B EFCAB13 FADS2 FAM208B FEM1A FOXE1 GIGYF1 GPR31 HECTD4 HIPK1 HORMAD2 HSPB9 IL15RA MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PHTF1 PTPN22 PUSL1 RAB2A RAB5B RASGRP1 RNASET2 RP3-462E2.3 SGK223 SLC1A2 TG TICAM1 TIMP4 TMOD1 TSTD2 UHRF1BP1 VAV3 VPS29
Hypothyroidism/myxoedema (self-reported)	34.42	50	46	102.2	1.00	2.3e-67	ADAM1A AL133458.1 ALDH16A1 ALDH2 ANP32B BACH2 BCL2L15 C1QTNF6 C9orf156 CAPZB COL15A1 DCLRE1B EFCAB13 FADS2 FAM208B FEM1A FOXE1 GIGYF1 GPR31 HECTD4 HIPK1 HORMAD2 HSPB9 IL15RA MMEL1 NAB1 NCBP1 NPEPPS NR3C2 OLFML3 PAM PHTF1 PTPN22 PUSL1 RAB2A RAB5B RASGRP1 RNASET2 RP3-462E2.3 SGK223 SLC1A2 TG TICAM1 TIMP4 TMOD1 TSTD2 U91328.19 UHRF1BP1 VAV3 VPS29
Rheumatoid Arthritis	12.81	13	8	17.8	0.94	2.3e-07	BCL2L15 DCLRE1B FAM208B GPR31 HECTD4 HIPK1 MMEL1 NAB1 OLFML3 PAM PHTF1 PTPN22 RASGRP1
Blood Eosinophil Count	12.02	17	13	28.9	0.72	3.0e-04	ADAM1A ALDH2 BACH2 EFCAB13 FADS2 FAM208B GIGYF1 GPR31 HECTD4 NAB1 NPEPPS RAB5B RASGRP1 RP3-462E2.3 SLC1A2 TIMP4 VPS29
Taking other prescription medications	6.41	11	7	15.6	0.98	7.8e-10	ADAM1A AL133458.1 BCL2L15 DCLRE1B FAM208B HECTD4 HIPK1 HSPB9 PTPN22 RNASET2 UHRF1BP1
Blood Platelet Count	6.36	15	10	22.2	0.28	2.2e-01	ADAM1A C1QTNF6 C9orf156 CAPZB FADS2 FOXE1 HECTD4 NAB1 PAM RP3-462E2.3 TIMP4 TMOD1 TSTD2 UHRF1BP1 VPS29
Blood White Count	5.85	18	15	33.3	0.37	8.3e-02	ADAM1A ALDH2 BACH2 BCL2L15 DCLRE1B FADS2 HECTD4 HORMAD2 HSPB9 OLFML3 PAM PHTF1 PTPN22 RAB2A RNASET2 RP3-462E2.3 TIMP4 VPS29
Crohns Disease (2017)	5.00	10	3	6.7	0.11	7.2e-01	AL133458.1 BCL2L15 DCLRE1B FADS2 GIGYF1 GPR31 HIPK1 HORMAD2 PTPN22 RNASET2
Crohns Disease (2012)	4.28	5	2	4.4	0.20	6.4e-01	AL133458.1 FADS2 HIPK1 HORMAD2 RNASET2
Long-standing illness, disability or infirmity	3.88	7	2	4.4	0.99	2.7e-08	AL133458.1 BCL2L15 DCLRE1B FAM208B PTPN22 RNASET2 UHRF1BP1
Number of treatments/medications taken	3.73	9	2	4.4	0.98	4.6e-09	ADAM1A AL133458.1 BCL2L15 DCLRE1B FADS2 FAM208B HECTD4 PTPN22 RNASET2
Number of self-reported non-cancer illnesses	3.54	6	1	2.2	0.98	1.5e-05	AL133458.1 ALDH2 FAM208B HECTD4 RNASET2 UHRF1BP1
Lupus	3.48	4	1	2.2	0.78	1.2e-01	DCLRE1B HECTD4 NAB1 SGK223
Diastolic blood pressure, automated reading	3.27	7	7	15.6	0.71	2.1e-02	ADAM1A ALDH2 GIGYF1 HECTD4 RP3-462E2.3 SGK223 VPS29
Irritable Bowel Disease (IBD)	3.25	4	2	4.4	0.90	6.5e-03	AL133458.1 HECTD4 HORMAD2 RNASET2
Primary Biliary Cirrhosis	3.15	3	0	0.0	0.86	1.4e-01	HECTD4 MMEL1 NAB1
Blood Red Count	2.96	15	11	24.4	0.59	1.0e-02	ADAM1A ALDH2 ANP32B BACH2 C9orf156 FADS2 GIGYF1 HECTD4 NAB1 NPEPPS PAM RAB5B RP3-462E2.3 TG VPS29
Coronary Artery Disease (CAD)	2.80	3	0	0.0	0.95	5.3e-02	HECTD4 UHRF1BP1 VPS29
Birth weight of first child	2.74	6	1	2.2	-0.72	4.3e-02	ADAM1A ALDH2 HECTD4 RAB2A RAB5B RP3-462E2.3
LDL Cholesterol	2.73	3	2	4.4	0.86	6.2e-02	ALDH2 FADS2 HECTD4
Birth weight	2.57	6	2	4.4	-0.97	2.6e-04	ADAM1A ALDH2 DCLRE1B HECTD4 HORMAD2 VPS29
Other serious medical condition/disability diagnosed by doctor	2.51	1	0	0.0	0.00	1.0e+00	DCLRE1B
Pulse rate, automated reading	2.48	6	3	6.7	-0.51	3.0e-01	FADS2 GIGYF1 NAB1 RAB5B UHRF1BP1 VPS29
Reaction Time	2.47	4	2	4.4	0.75	8.4e-02	ALDH2 HECTD4 RAB5B RP3-462E2.3
Medication: Atenolol	2.46	2	1	2.2	0.00	1.0e+00	ALDH2 HECTD4
Systolic Blood Pressure	2.42	7	7	15.6	0.87	2.3e-03	ADAM1A ALDH2 HECTD4 NAB1 PUSL1 RP3-462E2.3 VPS29
Hayfever, allergic rhinitis or eczema	2.41	6	3	6.7	-0.36	4.8e-01	ADAM1A BACH2 COL15A1 HECTD4 RAB5B U91328.19
Neuroticism score	2.38	4	1	2.2	0.53	4.7e-01	HORMAD2 SGK223 TIMP4 U91328.19
Loneliness, isolation	2.30	1	0	0.0	0.00	1.0e+00	RNASET2
Respiratory disease	2.27	4	3	6.7	-0.98	1.7e-02	BACH2 FADS2 FAM208B RAB5B
Mean time to correctly identify matches	2.25	3	2	4.4	0.98	3.2e-03	ALDH2 HECTD4 RP3-462E2.3
Hip circumference	2.24	9	5	11.1	-0.40	2.3e-01	ALDH2 EFCAB13 HECTD4 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Allergy or Eczema	2.23	5	4	8.9	-0.38	4.5e-01	ADAM1A BACH2 COL15A1 HECTD4 RAB5B
Cardiovascular Disease	2.20	6	3	6.7	0.82	1.2e-02	ADAM1A ALDH2 HECTD4 RAB5B UHRF1BP1 VPS29
Fed-up feelings	2.14	4	1	2.2	-0.78	6.6e-02	ALDH2 HECTD4 HORMAD2 SGK223
Mouth/teeth dental problems: Mouth ulcers	2.14	2	1	2.2	0.00	1.0e+00	FEM1A PAM
Neuroticism (Nagel 2018)	2.13	4	0	0.0	0.99	1.5e-04	AL133458.1 HORMAD2 RNASET2 TIMP4
Asthma (self-reported)	2.10	3	3	6.7	0.00	1.0e+00	BACH2 FADS2 RAB5B
Miserableness	2.08	2	1	2.2	0.00	1.0e+00	HORMAD2 SGK223
Vascular/heart problems diagnosed by doctor	2.08	5	4	8.9	-0.74	5.5e-02	ADAM1A ALDH2 HECTD4 SGK223 VPS29
Weight	2.07	9	5	11.1	-0.53	1.1e-01	ALDH2 ANP32B HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
High blood pressure	2.05	5	3	6.7	0.28	5.5e-01	ADAM1A ALDH2 HECTD4 RAB5B SGK223
Medication: Blood pressure	2.04	3	2	4.4	0.76	1.4e-01	ALDH2 HECTD4 SGK223
Diabetes diagnosed by doctor	2.03	1	0	0.0	0.00	1.0e+00	PTPN22
Arm predicted mass (left)	2.03	11	8	17.8	-0.70	8.1e-03	ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Depressed Affect (Nagel 2018)	2.02	2	0	0.0	0.00	1.0e+00	HECTD4 HORMAD2
Medication for cholesterol	2.01	1	0	0.0	0.00	1.0e+00	HECTD4
Worry too long after embarrassment	2.00	1	1	2.2	0.00	1.0e+00	SGK223
Arm fat-free mass (left)	2.00	11	9	20.0	-0.70	7.2e-03	ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Leg fat mass (left)	2.00	6	3	6.7	-0.45	3.1e-01	HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
HDL Cholesterol	1.99	2	1	2.2	0.00	1.0e+00	FADS2 UHRF1BP1
Asthma	1.99	3	3	6.7	0.00	1.0e+00	BACH2 FADS2 RAB5B
Arm predicted mass (right)	1.98	11	8	17.8	-0.68	1.5e-02	ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Allergy	1.97	6	3	6.7	0.13	8.1e-01	ADAM1A BACH2 COL15A1 FADS2 RAB5B U91328.19
Headache pain in last month	1.97	4	1	2.2	-0.92	2.7e-02	ALDH2 HECTD4 RAB5B U91328.19
Leg fat mass (right)	1.97	7	3	6.7	-0.47	2.4e-01	ALDH2 HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Hayfever/allergic rhinitis (self-reported)	1.96	2	0	0.0	0.00	1.0e+00	RAB5B U91328.19
Basal metabolic rate	1.95	13	7	15.6	-0.55	4.2e-02	ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Arm fat-free mass (right)	1.94	11	8	17.8	-0.69	1.4e-02	ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Smoking status: Previous	1.91	3	0	0.0	0.74	1.5e-01	ALDH2 HECTD4 RAB5B
Triglycerides	1.90	1	1	2.2	0.00	1.0e+00	FADS2
Past tobacco smoking	1.88	5	0	0.0	0.16	7.6e-01	ADAM1A ALDH2 HECTD4 PTPN22 RAB5B
Diabetes (self-reported)	1.88	1	0	0.0	0.00	1.0e+00	PTPN22
Pulse rate	1.88	2	2	4.4	0.00	1.0e+00	FADS2 GIGYF1
Leg fat-free mass (left)	1.86	10	8	17.8	-0.45	1.6e-01	ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Leg predicted mass (left)	1.86	10	7	15.6	-0.45	1.7e-01	ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Hypertension (Self-reported)	1.85	5	3	6.7	0.23	6.2e-01	ADAM1A ALDH2 HECTD4 RAB5B SGK223
Leg fat-free mass (right)	1.85	9	8	17.8	-0.43	2.2e-01	ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Leg predicted mass (right)	1.85	9	8	17.8	-0.43	2.2e-01	ANP32B EFCAB13 HECTD4 HORMAD2 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Whole body water mass	1.83	13	6	13.3	-0.58	3.0e-02	ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Worrier / anxious feelings	1.82	2	1	2.2	0.00	1.0e+00	PAM SGK223
Whole body fat-free mass	1.82	13	6	13.3	-0.57	3.2e-02	ADAM1A ALDH2 ANP32B EFCAB13 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 SGK223 U91328.19 UHRF1BP1 VPS29
Age started oral contraceptive pill	1.81	2	0	0.0	0.00	1.0e+00	RAB5B RNASET2
Neuroticism	1.80	4	0	0.0	0.43	5.7e-01	AL133458.1 C9orf156 HORMAD2 TIMP4
Body mass index (BMI)	1.80	6	4	8.9	-0.38	4.6e-01	HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Number of live births	1.79	2	0	0.0	0.00	1.0e+00	FADS2 HORMAD2
Worry (Nagel 2018)	1.78	5	0	0.0	0.67	2.2e-01	HORMAD2 PAM RNASET2 TIMP4 U91328.19
Whole body fat mass	1.77	8	2	4.4	-0.36	3.9e-01	ALDH2 ANP32B HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1 VPS29
Heel bone mineral density (BMD) T-score, automated (left)	1.74	3	1	2.2	0.00	1.0e+00	FADS2 SGK223 U91328.19
Heel bone mineral density (BMD) T-score, automated (right)	1.74	4	1	2.2	-0.39	6.1e-01	CAPZB FADS2 SGK223 U91328.19
Arm fat mass (right)	1.73	5	4	8.9	-0.41	4.9e-01	HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1
Trunk predicted mass	1.73	12	7	15.6	-0.73	3.2e-03	ADAM1A ALDH2 ANP32B COL15A1 HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 U91328.19 UHRF1BP1 VPS29
Suffer from 'nerves'	1.73	1	0	0.0	0.00	1.0e+00	SGK223
Medication: Blood pressure	1.72	3	1	2.2	0.88	1.2e-01	ADAM1A ALDH2 HECTD4
Leg fat percentage (left)	1.72	3	2	4.4	0.00	1.0e+00	SGK223 U91328.19 UHRF1BP1
Systolic blood pressure, automated reading	1.71	5	4	8.9	0.19	6.8e-01	ALDH2 HECTD4 NAB1 PUSL1 SGK223
Ever unenthusiastic/disinterested for a whole week	1.71	1	0	0.0	0.00	1.0e+00	TIMP4
Trunk fat-free mass	1.71	11	7	15.6	-0.72	5.4e-03	ADAM1A ALDH2 ANP32B HECTD4 HORMAD2 PUSL1 RAB5B RP3-462E2.3 U91328.19 UHRF1BP1 VPS29
Arm fat mass (left)	1.71	5	4	8.9	-0.39	5.1e-01	HECTD4 RAB5B SGK223 U91328.19 UHRF1BP1
Type 2 Diabetes (T2D) (2018)	1.70	2	0	0.0	0.00	1.0e+00	ADAM1A PAM
Trunk fat mass	1.70	3	2	4.4	0.00	1.0e+00	ANP32B U91328.19 UHRF1BP1
Pulse wave Arterial Stiffness index	1.70	1	1	2.2	0.00	1.0e+00	ADAM1A
Medication for pain relief, constipation, heartburn	1.70	1	1	2.2	0.00	1.0e+00	UHRF1BP1
Leg fat percentage (right)	1.69	3	2	4.4	0.00	1.0e+00	SGK223 U91328.19 UHRF1BP1
Pulse wave peak to peak time	1.69	1	1	2.2	0.00	1.0e+00	ADAM1A
Ever smoked	1.69	2	0	0.0	0.00	1.0e+00	HECTD4 PTPN22
Emphysema/chronic bronchitis	1.68	1	0	0.0	0.00	1.0e+00	SGK223
Irritability	1.67	2	1	2.2	0.00	1.0e+00	FADS2 SGK223
Mood swings	1.66	2	1	2.2	0.00	1.0e+00	HORMAD2 SGK223
Tense / 'highly strung'	1.65	2	1	2.2	0.00	1.0e+00	SGK223 TIMP4
Seen a psychiatrist for nerves, anxiety, tension or depression	1.64	2	0	0.0	0.00	1.0e+00	TIMP4 U91328.19
Medication: Lisinopril	1.64	1	0	0.0	0.00	1.0e+00	HECTD4
Neuroticism (2016)	1.63	1	1	2.2	0.00	1.0e+00	SGK223
Comparative height size at age 10	1.63	7	4	8.9	-0.95	1.4e-07	ALDH2 ANP32B C9orf156 CAPZB HECTD4 HORMAD2 NR3C2
Illnesses of father: Heart disease	1.63	1	0	0.0	0.00	1.0e+00	HECTD4
Nervous feelings	1.62	3	2	4.4	0.00	1.0e+00	HORMAD2 SGK223 U91328.19
Father's age at death	1.62	1	0	0.0	0.00	1.0e+00	HECTD4
Sensitivity / hurt feelings	1.59	1	1	2.2	0.00	1.0e+00	SGK223
Medication: Ibuprofen (e.g. Nurofen)	1.59	1	0	0.0	0.00	1.0e+00	HECTD4
Overall health rating	1.59	4	0	0.0	0.46	5.4e-01	BCL2L15 PTPN22 SGK223 UHRF1BP1
Medication for cholesterol, blood pressure or diabetes	1.55	1	0	0.0	0.00	1.0e+00	ADAM1A
Guilty feelings	1.54	1	0	0.0	0.00	1.0e+00	SGK223
Myopia	1.54	1	0	0.0	0.00	1.0e+00	FADS2
Frequency of tiredness / lethargy in last 2 weeks	1.52	1	0	0.0	0.00	1.0e+00	ALDH2
Fasting Glucose	1.51	1	0	0.0	0.00	1.0e+00	FADS2
Medication: Paracetamol	1.51	1	0	0.0	0.00	1.0e+00	RAB5B
Medication: Omeprazole	1.51	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Medication: Ramipril	1.50	1	0	0.0	0.00	1.0e+00	ADAM1A
Qualifications: NVQ or HND or HNC or equivalent	1.49	1	0	0.0	0.00	1.0e+00	ALDH2
High blood pressure (siblings)	1.46	1	0	0.0	0.00	1.0e+00	HECTD4
Chronotype (morning person)	1.45	4	0	0.0	0.48	4.1e-01	ALDH2 HECTD4 HORMAD2 TIMP4
Breastfed as a baby	1.45	1	1	2.2	0.00	1.0e+00	PUSL1
Body fat percentage	1.44	2	2	4.4	0.00	1.0e+00	U91328.19 UHRF1BP1
Impedance of arm (left)	1.41	8	4	8.9	0.66	5.5e-02	ADAM1A HECTD4 NR3C2 RAB5B RP3-462E2.3 SGK223 UHRF1BP1 VPS29
Breast Cancer	1.40	4	2	4.4	-0.98	3.0e-03	BCL2L15 DCLRE1B PHTF1 PTPN22
Impedance of arm (right)	1.39	7	4	8.9	0.55	2.0e-01	ADAM1A HECTD4 NR3C2 RAB5B SGK223 UHRF1BP1 VPS29
Trunk fat percentage	1.38	2	2	4.4	0.00	1.0e+00	U91328.19 UHRF1BP1
Gout (self-reported)	1.36	1	0	0.0	0.00	1.0e+00	HECTD4
Waist circumference	1.35	5	2	4.4	-0.51	3.9e-01	ALDH2 HECTD4 RAB5B U91328.19 UHRF1BP1
Mouth/teeth dental problems: Dentures	1.35	2	1	2.2	0.00	1.0e+00	SGK223 U91328.19
Pain experienced in last month	1.35	3	0	0.0	0.00	1.0e+00	ALDH2 HECTD4 RAB5B
BMI	1.33	4	2	4.4	-0.54	3.5e-01	HECTD4 RAB5B UHRF1BP1 VPS29
Bipolar Disorder or Schizophrenia	1.32	1	0	0.0	0.00	1.0e+00	SGK223
Arm fat percentage (left)	1.32	3	3	6.7	0.00	1.0e+00	SGK223 U91328.19 UHRF1BP1
Supplements: Fish oil (including cod liver oil)	1.31	1	0	0.0	0.00	1.0e+00	SGK223
Schizophrenia (2018)	1.30	1	0	0.0	0.00	1.0e+00	U91328.19
Supplements: Vitamin C	1.30	1	0	0.0	0.00	1.0e+00	U91328.19
Arm fat percentage (right)	1.29	3	2	4.4	0.00	1.0e+00	SGK223 U91328.19 UHRF1BP1
Qualifications: A levels/AS levels or equivalent	1.28	1	0	0.0	0.00	1.0e+00	RAB5B
High cholesterol (Self-reported)	1.28	1	0	0.0	0.00	1.0e+00	FADS2
Medication: Bendroflumethiazide	1.27	1	0	0.0	0.00	1.0e+00	SGK223
Waist Hip Ratio (WHR)	1.26	6	4	8.9	0.65	1.6e-01	ADAM1A BACH2 HECTD4 PAM TIMP4 UHRF1BP1
Vitamin and mineral supplements	1.26	1	0	0.0	0.00	1.0e+00	U91328.19
Serious illness, injury or assault to yourself	1.26	1	0	0.0	0.00	1.0e+00	PTPN22
Illnesses of siblings	1.26	2	0	0.0	0.00	1.0e+00	ADAM1A HECTD4
Mineral and other dietary supplements	1.26	1	0	0.0	0.00	1.0e+00	SGK223
Impedance of whole body	1.26	6	4	8.9	0.72	1.1e-01	ADAM1A HECTD4 RAB5B SGK223 UHRF1BP1 VPS29
Standing height	1.24	14	9	20.0	-0.29	2.1e-01	ALDH2 ANP32B C9orf156 CAPZB COL15A1 EFCAB13 FADS2 HECTD4 HORMAD2 HSPB9 NAB1 NPEPPS SGK223 U91328.19
Comparative body size at age 10	1.24	4	2	4.4	-0.59	4.1e-01	HORMAD2 SGK223 U91328.19 UHRF1BP1
Smoking Status	1.22	3	1	2.2	0.00	1.0e+00	ADAM1A PTPN22 RAB5B
Frequency of depressed mood in last 2 weeks	1.22	1	0	0.0	0.00	1.0e+00	HSPB9
Height	1.21	20	16	35.6	-0.51	7.0e-03	ADAM1A ALDH2 ANP32B C9orf156 CAPZB COL15A1 EFCAB13 FADS2 HECTD4 HORMAD2 HSPB9 NAB1 NCBP1 NPEPPS NR3C2 PAM PUSL1 RP3-462E2.3 SLC1A2 UHRF1BP1
Average weekly champagne plus white wine intake	1.19	1	0	0.0	0.00	1.0e+00	FADS2
Commuting to job workplace: Cycle	1.19	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Bipolar Disorder (2018)	1.18	1	0	0.0	0.00	1.0e+00	FADS2
Verbal and Numeric Reasoning (VNR)	1.18	3	0	0.0	0.00	1.0e+00	FADS2 PAM RAB5B
Exposure to tobacco smoke at home	1.18	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Peak expiratory flow (PEF)	1.18	2	2	4.4	0.00	1.0e+00	PUSL1 SGK223
Lung FEV1/FVC ratio	1.16	5	3	6.7	-0.65	2.4e-01	ANP32B C9orf156 NCBP1 RAB5B SLC1A2
Lung FVC	1.16	7	1	2.2	0.13	7.7e-01	ALDH2 HECTD4 HORMAD2 HSPB9 PAM RAB5B RP3-462E2.3
Impedance of leg (right)	1.16	4	3	6.7	0.57	4.3e-01	PAM RAB5B SGK223 UHRF1BP1
Average weekly beer plus cider intake	1.16	1	0	0.0	0.00	1.0e+00	SGK223
HbA1C	1.13	1	0	0.0	0.00	1.0e+00	ADAM1A
Age at first live birth	1.13	1	0	0.0	0.00	1.0e+00	RAB5B
Forced expiratory volume in 1-second (FEV1)	1.10	4	2	4.4	-0.59	4.1e-01	HORMAD2 RAB5B SGK223 U91328.19
Impedance of leg (left)	1.09	4	3	6.7	0.56	4.4e-01	PAM RAB5B SGK223 UHRF1BP1
Medication: Ventolin 100micrograms inhaler	1.08	2	0	0.0	0.00	1.0e+00	BACH2 RAB5B
Qualifications: None of the above	1.07	1	1	2.2	0.00	1.0e+00	RAB5B
Wheeze or whistling in the chest in last year	1.07	1	0	0.0	0.00	1.0e+00	FADS2
Unable to work because of sickness or disability	1.06	1	0	0.0	0.00	1.0e+00	UHRF1BP1
Schizophrenia (2014)	1.05	2	0	0.0	0.00	1.0e+00	GIGYF1 SGK223
Medication: Simvastatin	1.05	1	0	0.0	0.00	1.0e+00	FADS2
Fluid intelligence score	1.05	2	0	0.0	0.00	1.0e+00	FADS2 RAB5B
Hearing difficulty/problems with background noise	1.04	1	0	0.0	0.00	1.0e+00	U91328.19
Friendships satisfaction	1.04	1	0	0.0	0.00	1.0e+00	VPS29
Schizophrenia vs Biploar Disorder	1.01	1	0	0.0	0.00	1.0e+00	VPS29
Sitting height	1.00	8	4	8.9	-0.32	4.1e-01	ANP32B C9orf156 CAPZB COL15A1 FADS2 HORMAD2 U91328.19 UHRF1BP1
Qualifications: College or University degree	1.00	3	1	2.2	0.00	1.0e+00	PAM RAB5B U91328.19
Forced expiratory volume in 1-second (FEV1), predicted percentage	0.99	2	1	2.2	0.00	1.0e+00	RAB5B U91328.19
Relative age voice broke	0.97	1	0	0.0	0.00	1.0e+00	ADAM1A
Alcohol intake frequency.	0.97	2	0	0.0	0.00	1.0e+00	NPEPPS RAB5B
Forced expiratory volume in 1-second (FEV1), Best measure	0.95	3	1	2.2	0.00	1.0e+00	HORMAD2 RAB5B SGK223
Forced vital capacity (FVC)	0.89	2	1	2.2	0.00	1.0e+00	HORMAD2 RAB5B
Heel T-Score	0.84	8	4	8.9	0.09	8.3e-01	ANP32B BACH2 CAPZB DCLRE1B FADS2 NAB1 PUSL1 RAB5B
Hair/balding pattern: Pattern 4	0.81	1	0	0.0	0.00	1.0e+00	FADS2
Intelligence (Savage-Jansen 2018)	0.80	3	0	0.0	0.00	1.0e+00	FADS2 PAM RAB5B
Forced vital capacity (FVC), Best measure	0.73	2	1	2.2	0.00	1.0e+00	HORMAD2 RAB5B
Hair Pigment	0.54	9	7	15.6	0.33	2.2e-01	ALDH2 ANP32B C9orf156 EFCAB13 FADS2 GIGYF1 HECTD4 RP3-462E2.3 TSTD2
Tanning	0.30	3	0	0.0	0.98	2.2e-02	ALDH2 HECTD4 RP3-462E2.3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellar Hemisphere	7	0.470	1.9
GTEx	Brain Cerebellum	7	0.353	1.9
GTEx	Brain Frontal Cortex BA9	5	0.541	1.9
GTEx	Brain Putamen basal ganglia	2	0.321	1.9
GTEx	Uterus	2	0.353	1.9
GTEx	Whole Blood	7	0.351	1.9
NTR	Blood	6	0.250	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.584	1.9
GTEx	Adrenal Gland	4	0.275	1.8
GTEx	Artery Tibial	10	0.266	1.8
GTEx	Esophagus Gastroesophageal Junction	7	0.484	1.8
GTEx	Lung	8	0.278	1.8
GTEx	Nerve Tibial	12	0.278	1.8
GTEx	Ovary	4	0.441	1.8
GTEx	Skin Not Sun Exposed Suprapubic	8	0.325	1.8
GTEx	Small Intestine Terminal Ileum	0	0.000	1.8
GTEx	Stomach	7	0.481	1.8
GTEx	Testis	12	0.380	1.8
GTEx	Thyroid	13	0.325	1.8
GTEx	Vagina	0	0.000	1.8
YFS	Blood	11	0.238	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.241	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.603	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8
GTEx	Adipose Subcutaneous	6	0.172	1.7
GTEx	Artery Aorta	3	0.101	1.7
GTEx	Artery Coronary	4	0.338	1.7
GTEx	Brain Caudate basal ganglia	1	0.109	1.7
GTEx	Brain Cortex	3	0.290	1.7
GTEx	Brain Hippocampus	1	0.191	1.7
GTEx	Breast Mammary Tissue	5	0.253	1.7
GTEx	Breast Mammary Tissue (Female)	4	0.243	1.7
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.7
GTEx	Cells Transformed fibroblasts	10	0.238	1.7
GTEx	Colon Sigmoid	4	0.274	1.7
GTEx	Colon Transverse	10	0.484	1.7
GTEx	Esophagus Mucosa	7	0.211	1.7
GTEx	Esophagus Muscularis	7	0.217	1.7
GTEx	Heart Atrial Appendage	4	0.253	1.7
GTEx	Liver	1	0.139	1.7
GTEx	Muscle Skeletal	9	0.311	1.7
GTEx	Pituitary	2	0.179	1.7
GTEx	Prostate	2	0.240	1.7
GTEx	Skin Sun Exposed Lower leg	10	0.275	1.7
GTEx	Spleen	1	0.071	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	11	0.250	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	7	0.257	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	9	0.209	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.362	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	6	0.204	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.120	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.289	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	10	0.194	1.7
GTEx	Adipose Visceral Omentum	4	0.196	1.6
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.6
GTEx	Breast Mammary Tissue (Male)	4	0.335	1.6
GTEx	Heart Left Ventricle	5	0.327	1.6
GTEx	Pancreas	2	0.123	1.6
METSIM	Adipose	12	0.260	1.6
ROSMAP	Brain Pre-frontal Cortex	8	0.182	1.6
CommonMind	Brain Pre-frontal Cortex	12	0.223	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	7	0.339	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.294	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.195	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.251	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.6
GTEx	Brain Hypothalamus	1	0.169	1.5
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	3	0.073	1.5